**Table e-3. Demographics and clinical features of patients with confirmed COVID-19 and those without COVID-19**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Confirmed COVID-19****(n=5)** | **No COVID-19** **(n = 356)** | ***p* Value** |
| **Female, n (%)** | 2 (22.2) | 239 (67.1) | 0.340 |
| **Age at survey, y, median (range)** | 52 (28-69) | 48 (20-86) | 0.690 |
| **At least 1 comorbid condition, n (%)** **Smoking**  **Dyslipidemia** **Diabetes** **Hypertension** **Heart disease** **Pulmonary disease** **Malignancy** | 00000000 | 167 (47.1)65 (18.2)78 (21.9)24 (6.7)54 (15.1)8 (2.2)17 (4.8)8 (2.2) | 0.0470.5000.5901.001.001.001.001.00 |
| **MS type, n (%)****RRMS****SPMS****PPMS****CIS** | 4 (80)1 (20)00 | 298 (83.7)31 (8.7)22 (6.2)5 (1.4) | 0.780 |
| **Disease duration, y , mean (SD)** | 16.4 (8.3) | 15.4 (9.7) | 0.800 |
| **Annualized relapse rate, mean (SD)** | 0.46 (0.27) | 0.4 (0.3) | 0.560 |
| **Last EDSS score, median (range)** | 2.0 (2.0-3.0) | 2.0 (0-8.0) | 0.170 |
| **Disease modifying treatment, n (%)** | 5 (100) | 264 (74.1) | 0.330 |
|  **Interferon beta** **Glatiramer acetate** **Dimethylumarate** **Teriflunomide** **Ocrelizumab** **Rituximab** **Natalizumab** **Fingolimod** **Alemtuzumab** **Cladribine** **Ofatumumab** **Azathioprine** **Ponesimod** | 1 (20)01 (20)001 (20)1 (20)001 (20)000 | 60 (22.6)35 (13.2)50 (18.9)30 (11.3)10 (3.7)17 (6.4)14 (5.3)34 (12.8)4 (1.5)5 (1.9)2 (0.7)1 (0.3)2 (0.7) |  |
| **Patients who developed MS Relapse during the study period, n (%)** | 0 | 6 (1.7) | 1.00 |